PL3220891T3 - Preparat podjęzykowy riluzolu - Google Patents
Preparat podjęzykowy riluzoluInfo
- Publication number
- PL3220891T3 PL3220891T3 PL15823415T PL15823415T PL3220891T3 PL 3220891 T3 PL3220891 T3 PL 3220891T3 PL 15823415 T PL15823415 T PL 15823415T PL 15823415 T PL15823415 T PL 15823415T PL 3220891 T3 PL3220891 T3 PL 3220891T3
- Authority
- PL
- Poland
- Prior art keywords
- riluzole
- sublingual formulation
- sublingual
- formulation
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960004181 riluzole Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083094P | 2014-11-21 | 2014-11-21 | |
| EP15823415.3A EP3220891B1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
| PCT/US2015/061114 WO2016081472A1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3220891T3 true PL3220891T3 (pl) | 2020-08-24 |
Family
ID=55085882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15823415T PL3220891T3 (pl) | 2014-11-21 | 2015-11-17 | Preparat podjęzykowy riluzolu |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11660267B2 (OSRAM) |
| EP (3) | EP4039247B1 (OSRAM) |
| JP (3) | JP6753860B2 (OSRAM) |
| KR (2) | KR102580378B1 (OSRAM) |
| CN (1) | CN107249567B (OSRAM) |
| AU (2) | AU2015350148B2 (OSRAM) |
| BR (1) | BR112017010423B1 (OSRAM) |
| CA (1) | CA2967662A1 (OSRAM) |
| CY (1) | CY1122469T1 (OSRAM) |
| DK (1) | DK3220891T3 (OSRAM) |
| EA (1) | EA038518B1 (OSRAM) |
| ES (2) | ES2751300T3 (OSRAM) |
| HR (1) | HRP20191892T8 (OSRAM) |
| HU (1) | HUE046869T2 (OSRAM) |
| IL (2) | IL278188B2 (OSRAM) |
| LT (1) | LT3220891T (OSRAM) |
| MX (1) | MX368838B (OSRAM) |
| PH (1) | PH12017500934B1 (OSRAM) |
| PL (1) | PL3220891T3 (OSRAM) |
| PT (1) | PT3220891T (OSRAM) |
| RS (1) | RS59490B1 (OSRAM) |
| SG (1) | SG11201703896QA (OSRAM) |
| SI (1) | SI3220891T1 (OSRAM) |
| WO (1) | WO2016081472A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3038979A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3755332A1 (en) * | 2018-02-21 | 2020-12-30 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| JP2021525714A (ja) * | 2018-05-27 | 2021-09-27 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． | 疾患の処置のためのリルゾール口腔内崩壊錠の使用 |
| JP2021534160A (ja) * | 2018-08-16 | 2021-12-09 | バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
| MX2022004808A (es) * | 2019-10-22 | 2022-06-08 | Arvinas Operations Inc | Métodos para tratar el cáncer de próstata. |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| WO2022103636A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Improved use of cannabinoids in the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
| KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| WO1995001782A2 (en) | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| DK0946111T3 (da) * | 1996-12-20 | 2004-06-21 | Nutrinova Gmbh | Fremgangsmåde til forstærkning af sødekraften og til smagsforbedring af en blanding af højintensive sødestoffer |
| DE69840495D1 (de) | 1997-02-20 | 2009-03-12 | Massachusetts Inst Technology | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben |
| JP4947833B2 (ja) | 1997-07-25 | 2012-06-06 | アルペックス・ファルマ・ソシエテ・アノニム | 速崩壊性口内溶解錠の製造に適した顆粒の製造方法 |
| US7939105B2 (en) | 1998-11-20 | 2011-05-10 | Jagotec Ag | Process for preparing a rapidly dispersing solid drug dosage form |
| AU2173400A (en) * | 1998-12-09 | 2000-06-26 | Chiron Corporation | Method for administering agents to the central nervous system |
| FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
| US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| EP1443912B1 (en) | 2001-10-12 | 2007-08-29 | Elan Pharma International Limited | Compositions having a combination of immediate release and controlled release characteristics |
| WO2003068604A1 (en) | 2002-02-13 | 2003-08-21 | Weibel Michael K | Drug dose-form and method of manufacture |
| CA2477088A1 (en) * | 2002-02-22 | 2003-10-02 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2004105756A2 (en) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| EP2170282A4 (en) | 2007-06-27 | 2014-11-05 | Hanmi Pharm Ind Co Ltd | METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION |
| WO2010009279A1 (en) * | 2008-07-15 | 2010-01-21 | University Of Medicine And Dentistry Of New Jersey | Methods and compositions for treating alzheimer's disease |
| US8414356B2 (en) | 2008-10-31 | 2013-04-09 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8545806B2 (en) | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| WO2010096869A1 (en) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart |
| EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| TR201809351T4 (tr) * | 2011-03-01 | 2018-07-23 | Pharnext | Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi. |
| UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| WO2013010015A2 (en) * | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination als therapy |
| CA2864008C (en) * | 2012-03-01 | 2020-04-21 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| EA201791110A1 (ru) | 2014-11-21 | 2017-11-30 | Биохэвен Фармасьютикэл Холдинг Компани Лтд. | Сублингвальное введение рилузола |
| RS62915B1 (sr) * | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
-
2015
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 CA CA2967662A patent/CA2967662A1/en active Pending
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2015-11-17 EP EP21169884.0A patent/EP4039247B1/en active Active
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/en not_active Ceased
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/en active Active
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active Active
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 PH PH1/2017/500934A patent/PH12017500934B1/en unknown
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/en active Active
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 KR KR1020237031525A patent/KR102811263B1/ko active Active
- 2015-11-17 IL IL278188A patent/IL278188B2/en unknown
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
-
2019
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-25 US US17/079,498 patent/US12121609B2/en active Active
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
-
2024
- 2024-10-21 US US18/921,046 patent/US20250114301A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278188A (en) | Sublingual formulation of riluzole | |
| IL250089A0 (en) | Metrology of multiple sampling processes | |
| SG11201609265RA (en) | Characterizing states of subject | |
| IL252283A0 (en) | Sublingual administration of riluzole | |
| AP2016009496A0 (en) | Substituted spirocydic inhibitors of autotaxin | |
| SI3102555T1 (sl) | Sestavki spojin in njihove uporabe | |
| SI3524234T1 (sl) | Trdne oblike sofosbuvira | |
| ZA201700022B (en) | A novel formulation of meloxicam | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| GB201407822D0 (en) | Use of a composition | |
| IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
| GB2544217B (en) | Chlorination of sucrose-6-esters | |
| IL249332A0 (en) | Crystalline forms of sofosbuvir | |
| HK1242593A1 (en) | Sublingual administration of riluzole | |
| GB201412359D0 (en) | Composition of objects | |
| GB201412089D0 (en) | Composition of objects | |
| GB201418410D0 (en) | use of compositions of matter | |
| GB201418230D0 (en) | Construction of surfaces | |
| HUP1400294A2 (hu) | Clopidogrel új alkalmazása | |
| GB201417348D0 (en) | Prodrugs of lxazomib | |
| GB201417347D0 (en) | Prodrugs of delanzomib | |
| GB201405157D0 (en) | Theory of international law | |
| GB201405142D0 (en) | Theory of restoration | |
| GB201404705D0 (en) | Theory of Conceptual art | |
| TWM489614U (en) | Structure of bathroom accessory |